Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

 has evolved significantly in 2025, with the key approvals from the 

 of inclisiran and plozasiran and the major trial advances of olezarsen and enlicitide. 

, hypercholesterolemia, and LDL-C management have all received crucial new preventive or protective measures during the course of the year, providing new resources for historically underserved populations.

Given the amount of critical news from 2025, the editorial team at 

 has collected 13 of the most impactful headlines from the last 12 months, including FDA announcements, critical trial results, and key clinician insights. Catch up on anything you may have missed below.


FDA Approves Inclisiran (Leqvio) Label Update as First-Line Monotherapy in Hypercholesterolemia

On July 31, 2025, inclisiran’s label was updated to allow its use as a first-line monotherapy, along with diet and exercise, to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia. Parent company Novartis announced the FDA’s proactive request of the label update, based on the robust LDL-C lowering data for PCSK9-targeting therapies. Prior to the update, inclisiran was required to be used on top of or in combination with statin therapy – the update also revised instances of “primary hyperlipidemia” to “hypercholesterolemia” to enhance focus on LDL-C reduction.


FDA Approves Plozasiran for Adults With Familial Chylomicronemia Syndrome

Plozasiran was approved on November 18, 2025, for the reduction of triglycerides in adult patients with familial chylomicronemia syndrome (FCS). The first-in-class RNA interference therapeutic is designed to reduce the production of apoC-III, a major component of triglyceride-rich lipoproteins and a regulator of triglyceride metabolism. The approval was based on the PALISADE trial, which saw patients receiving plozasiran exhibit an 80% median change in triglycerides from baseline and an 83% decreased risk of acute pancreatitis compared to placebo.


FDA Approves Lerodalcibep-liga (Lerochol) for LDL-C Reduction in Hypercholesterolemia

On December 15, 2025, the FDA approved lerodalcibep-liga, under the brand name Lerochol, as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). The novel, small protein-binding, third-generation PCSK9 inhibitor, designed as a once-monthly, single small-volume subcutaneous injections for LDL-C lowering, was approved on the back of the LIBerate program, a series of 5 phase 3 registration studies including 2900 patients.


CORALreef Lipids: Enlicitide Lowers LDL-C as Much as Injectables, With Ann Marie Navar, MD, PhD

The CORALreef Lipids phase 3 trial highlighted the efficacy of an oral, once-daily dose of PCSK9 inhibitor enlicitide in significantly reducing LDL-C compared to placebo in patients with hypercholesterolemia with or at risk of 

atherosclerotic cardiovascular disease (ASCVD)

. The 24-week trial compared enlicitide 20 mg to placebo, displaying an LDL-C reduction of ≤60% in the enlicitide cohort, which was maintained at 52 weeks. Patients also saw a 53% reduction in non-HDL, a 50% reduction in ApoB, and a 28% reduction in Lp(a).


CORE/CORE2: Olezarsen Achieves Primary Endpoint in Severe Hypertriglyceridemia

The phase 3 CORE and CORE2 trials both highlighted olezarsen’s capacity for substantial reductions in fasting triglyceride levels among patients with severe hypertriglyceridemia. The investigative antisense oligonucleotide slows triglyceride clearance by inhibiting lipoprotein lipase activity and the liver’s uptake of triglyceride-rich particles. During the trials, olezarsen demonstrated a placebo-adjusted mean reduction in fasting triglyceride of ≤72% at 6 months, which was sustained for the full 12-month trial period.


VICTORION-Difference: Inclisiran Achieves Primary Endpoint of LDL-C Reduction Versus Placebo

Patients with hypercholesterolemia at high or very high risk of cardiovascular events reached LDL-C goals with inclisiran on top of individually optimized lipid-lowering therapy than with placebo in the VICTORION-Difference trial. The small interfering ribonucleic acid targeting PCSK9 messenger RNA provides a consistent reduction in LDL-C when given twice yearly after initial doses. VICTORION-Difference saw 84.9% of patients in the inclisiran arm achieve guideline-recommended LDL-C goals compared to 31% receiving placebo.


Study Finds Icosapent Ethyl Can Reduce Cardiovascular Risk, Even in Well-Controlled LDL-C

The landmark REDUCE-IT trial further examined icosapent ethyl’s cardiovascular benefits for patients, regardless of their baseline LDL-C levels. The trial was the basis for icosapent ethyl’s 2019 FDA approval for reducing cardiovascular risk as an adjunct to maximally tolerated statin therapy in adults with triglyceride levels ≥150 mg/dL and established cardiovascular disease. This secondary analysis examined a composite endpoint of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina based on baseline LDL-C level.


Obicetrapib Achieves Robust LDL-C Reductions in Phase 3 ASCVD Trials

In the BROADWAY and TANDEM phase 3 trials, once-daily oral obicetrapib substantially reduced LDL-C in patients with ASCVD when used as an adjunct to statins. The BROADWAY trial saw obicetrapib achieve a 33% reduction in LDL-C on top of maximally tolerated lipid-lowering therapies, along with a 21% relative reduction in major adverse cardiovascular events. TANDEM saw a fixed-dose combination of obicetrapib and ezetimibe meet all primary endpoints for LDL-C reduction compared with placebo.


RX Review: Updates and Unmet Needs for Familial Chylomicronemia Syndrome

In the first of a 7-part video series discussing recent changes in therapeutic options for patients with FCS, host Viet Le, DMSc, PA-C, a preventive cardiology PA at Intermountain Health and former president of the Academy of Physician Associates in Cardiology, spoke with Christie Ballantyne, MD, chief of cardiovascular research at Baylor College of Medicine and principle investigator in the PALISADE trial, to highlight the challenges and treatment gaps present in FCS care. However, Ballantyne ultimately marks 2025 as a turning point for FCS, with the approval of plozasiran on November 18 and olezarsen’s approval in late 2024 providing targeted therapies capable of substantially reducing triglycerides.


RX Review: Integrating New Therapies in FCS Treatment Algorithms


In the fourth part of this 7-part series, host Viet Le, DMSc, PA-C, and guest Christie Ballantyne, MD, discuss plozasiran and its newfound role in contemporary FCS management. Ballantyne discusses the mechanism of action of small interfering RNA therapies like plozasiran and how they modulate pathways independent of lipoprotein lipase activity. Additionally, the pair discuss how plozasiran expands treatment options in this historically underserved population.


RX Review: Understanding Plozasiran’s Role in FCS Management


In the fifth episode of this 7-part series, host Viet Le, DMSc, PA-C, and guest Christie Ballantyne, MD, discussed the effect olezarsen and plozasiran have had on treatment algorithms for FCS. While the approvals are groundbreaking, Ballantyne cautions careful attention when implementing the new medications, with particular attention to patient needs and existing management principles. He also emphasizes the importance of consistent lipid monitoring and clear communication across the various related specialties, including nutritionists, cardiologists, and lipid specialists.

Articles

Lipid management in 2025 has seen significant advancements with FDA approvals of inclisiran, plozasiran, and lerodalcibep-liga, alongside major trial results for olezarsen and enlicitide. These developments offer new preventive measures for ischemic stroke, hypercholesterolemia, and LDL-C management, particularly benefiting underserved populations. Key trials like CORALreef Lipids and VICTORION-Difference have demonstrated the efficacy of novel therapies in reducing LDL-C and triglycerides. Additionally, the REDUCE-IT trial highlighted icosapent ethyl's cardiovascular benefits, while obicetrapib showed robust LDL-C reductions in ASCVD patients.

Catch up on the most impactful headlines in dyslipidemia from all of 2025 with our Year in Review.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

FDA News

Dyslipidemia in 2025: Year in Review

Image Credit: US Food and Drug Administration

Announced by parent company MannKind Corporation on December 23, 2025, the 

 has approved a supplemental New Drug Application (sNDA) for the furosemide On-body Infusor (FUROSCIX) to treat edema associated with 

 in pediatric patients weighing ≥43 kg.

“We are pleased to make FUROSCIX available to the pediatric population, a highly specific patient group, offering a convenient option outside the hospital setting for those who meet the weight criteria,” Ajay Ahuja, MD, MBA, chief medical officer of MannKind Corporation, said in a statement.

The FUROSCIX On-body Infusor was initially approved in 2022 for the treatment of edema in adults with chronic HF; later, in 2025, it received approval for adults with CKD as well. This third approval fulfills all post-marketing requirements outlined in the initial approval letter under the Pediatric Research Equity Act.

Furosemide’s initial approval was based on data from the phase 2 AT HOME-HF pilot study, a multicenter, randomized trial investigating subcutaneous furosemide 80 mg/10 mL versus standard of care in 51 patients with chronic HF and worsening congestion, uncontrolled by diuresis. The primary endpoint was a win ratio of a 30-day hierarchy composite of cardiovascular death, HF events, and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP). Secondary endpoints included dyspnea severity, functional capacity, and quality of life.

Ultimately, 51 patients were enrolled and randomly assigned in a 2:1 ratio to either furosemide (n = 34) or standard of care (n = 17). Furosemide displayed greater reductions in body weight; between-group difference in least square mean change was -2.02 kg at day 3 (95% CI, -3.9 to -0.14; 

 = .035). Additionally, the furosemide-to-standard-of-care win ratio was 1.11 (95% CI, 0.48 to 2.5; 

 = .806). The most common adverse event with furosemide at the time was mild infusion site pain (11.8%).

In the same release, MannKind announced the FDA’s acceptance of a separate sNDA for the FUROSCIX ReadyFlow Autoinjector for adult patients with chronic HF or CKD. Unlike the On-body Infusor, the ReadyFlow is designed to deliver a subcutaneous furosemide injection in <10 seconds. If approved, the device could provide patients with a method of managing fluid buildup from home, eliminating the need for hospital admission.

“The FUROSCIX ReadyFlow Autoinjector marks a key milestone in expanding patient options and improving care,” Michael Castagna, PharmD, chief executive officer at MannKind Corporation, said in a separate statement regarding the acceptance. “By delivering treatment in under 10 seconds, the ReadyFlow Autoinjector has the potential to transform how adults with chronic heart failure or chronic kidney disease manage episodes of fluid buildup—providing faster relief, reducing hospital admissions, and lowering overall healthcare costs.”

The FUROSCIX ReadyFlow Autoinjector has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 26, 2026.

MannKind Corporation. MannKind Shares FUROSCIX Business Updates. December 23, 2025. Accessed December 23, 2025. 

https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-shares-furoscixr-business-updates

Konstam MA, Massaro J, Dhingra R, et al. Avoiding Treatment in Hospital With Subcutaneous Furosemide for Worsening Heart Failure: A Pilot Study (AT HOME-HF). JACC Heart Fail. 2024;12(11):1830-1841. 

MannKind Corporation. MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease. December 1, 2025. Accessed December 23, 2025. 

https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-us-fda-accepts-review-its-supplemental-new

The FDA has approved a supplemental New Drug Application for the FUROSCIX On-body Infusor to treat edema in pediatric patients with chronic heart failure and chronic kidney disease. Initially approved for adults, this marks the third approval for FUROSCIX, fulfilling Pediatric Research Equity Act requirements. The approval was based on the AT HOME-HF pilot study, which showed significant weight reduction in patients. Additionally, the FDA is reviewing the FUROSCIX ReadyFlow Autoinjector, designed for rapid subcutaneous furosemide delivery, with a decision expected by July 2026.

The FDA has approved an sNDA for the FUROSCIX On-body Infusor in pediatric patients and accepted another for the FUROSCIX ReadyFlow Autoinjector.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

FDA Approves FUROSCIX On-Body Injector for Pediatric Patients, Accepts sNDA for ReadyFlow Autoinjector

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

A new study reported that participants with 

demonstrated significantly greater levels of 

generalized anxiety, social anxiety, depression, and perceived stress 

compared with those without the condition.

“…due to the limited number of studies focusing on single symptoms, a meta-analysis could not be conducted across these dimensions,” wrote investigator Yuan Kong, from the Beijing Changping Hospital of Integrated Chinese and Western Medicine, and colleagues.

Not only does hair perform essential biological and psychosocial functions, including scalp protection, sensory perception, and sebum regulation, but it has a meaningful impact on body image. People with this type of hair loss may experience lowered self-esteem, anxiety, and depression, which ultimately can hinder quality of life and social functioning.

Androgenetic alopecia carries a substantial health burden, affecting up to 50% of the male population by age 50 and up to 80% by age 80. Female hair loss occurs in approximately 12% of women by age 30, 25% by age 49, and 30% to 40% of women aged 60 to 69 years.

Hair loss in women, although generally less severe than in men, is discussed less often and is a source of shame for many individuals living with the condition. Many women believe they are alone in their experience with androgenetic alopecia and may feel a loss of femininity and youth.

Studies dating back to the 1990s reported the links between advanced hair loss and stress related to socioemotional functioning, self-esteem, positive life events, and coping behaviors.

A 2023 study found that among 1230 male patients diagnosed with androgenetic alopecia, 95% experienced stress and 78% felt embarrassed by their hair loss. Another study showed that patients with androgenetic alopecia demonstrated greater somatization, depression, and hostility.

While numerous studies have shown greater rates of depression in patients with androgenetic alopecia, other studies have reported no significant association between depression and this type of hair loss. These conflicting findings emphasize the need for further research on depression in this patient population.

Moreover, research on psychological well-being in individuals with androgenetic alopecia remains limited by a narrow focus on physiological outcomes, small and inconsistent samples, and incomplete assessment of psychological domains, often without appropriate non-androgenetic alopecia comparison groups or representation from Asian populations. To address these gaps, investigators compared the psychological well-being between androgenetic alopecia and non-androgenetic alopecia populations using broader, multinational data that include both sexes, multiple assessment scales, and studies from China, to inform prevention and intervention strategies.

The team conducted a systematic search of CNKI, Wanfang, PubMed, Web of Science, Cochrane, EMBASE, and EBSCO from inception to June 30, 2025. In total, 13 studies were included, comprising 2737 patients with androgenetic alopecia and 17,382 controls.

Compared with controls, patients with androgenetic alopecia demonstrated significantly greater levels of generalized anxiety symptoms (pooled SMD, -0.50; 95% confidence interval [CI], -0.99 to 0.00; 

 =.05), social anxiety symptoms (pooled SMD, -0.50; 95% CI, -0.84 to -0.16; 

 =.004), depression symptoms (pooled SMD, -0.38; 95% CI, -0.65 to -0.12; 

 =.004), and perceived stress (pooled SMD, -1.09; 95% CI, -1.43 to -0.74; 

 <.001). Investigators observed no significant difference in general distress between patients with and without androgenetic alopecia (pooled SMD, -0.01; 95% CI, -0.39 to 0.37;

Consistent with previous studies, Kong and colleagues observed reduced self-esteem, life satisfaction, and emotional intelligence dimensions, along with greater body image dissatisfaction, somatization, interpersonal sensitivity, and psychoticism, in patients with androgenetic alopecia.

“Future research and clinical practice should focus on the psychological health of AGA patients,” investigators concluded.

 “First, psychological assessment should be incorporated into the routine clinical process. Standardized psychological scales should be used to comprehensively evaluate patients’ anxiety, depression, stress, and other psychological states, to detect…potential problems in time. Second…dermatologists should work together with psychologists to provide comprehensive treatment plans for patients. For example, patients with significant anxiety and depression symptoms should be referred to psychologists for cognitive-behavioral therapy or pharmacotherapy.”

Kong Y, Shang Y, Zhang L. Association between androgenetic alopecia and psychological well-being: a systematic review and meta-analysis. 

. 2025;16:1705957. Published 2025 Nov 26. 

Androgenetic alopecia: A Guide to Pattern Hair Loss. Ishrs. Accessed December 23, 2025. 

Androgenetic alopecia significantly impacts psychological well-being, with affected individuals experiencing higher levels of anxiety, depression, and stress compared to those without the condition. The condition affects a substantial portion of the population, with notable differences in prevalence between genders. Despite existing research, inconsistencies in findings highlight the need for further studies, particularly focusing on depression. Comprehensive psychological assessments should be integrated into clinical practice, and collaboration between dermatologists and psychologists is recommended to provide holistic treatment plans, including cognitive-behavioral therapy or pharmacotherapy for those with severe symptoms.

A review found increased anxiety, depression, social anxiety, and perceived stress among individuals with androgenetic alopecia compared with those without the condition.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Alopecia

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Psychological Distress Greater in Patients With Androgenetic Alopecia

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN)

 impose a significant, disruptive burden on patients and their caregivers, according to findings from a recent study.

Although a majority of patients in this real-world cohort reported slow, stable, or improving disease progression, results still conveyed substantial and persistent clinical, economic, and quality-of-life impacts among patients with these glomerular diseases.¹

“This real-world study aimed to assess the clinical, economic, and humanistic burden of these conditions in Europe and the United States, addressing key evidence gaps,” wrote study investigator Carly Rich, PhD, the global director of the Swedish Orphan Biovitrum (SOBI), and colleagues.

C3G and IC-MPGN are rare, serious chronic kidney diseases that can have a considerable individual impact. Common clinical manifestations include proteinuria, fatigue, low energy levels, edema, and hypertension, with diagnoses often occurring incidentally because of nonspecific symptoms.

The lifelong persistence of symptoms can negatively affect daily functioning, psychological health, and overall well-being. In addition, frequent healthcare visits, hospitalizations, and the need for dialysis in a subset of patients contribute to substantial economic strain on patients, families, and caregivers. Yet, the real-world impact on patients and families affected by these glomerular diseases has not been assessed.

In a multinational, cross-sectional survey, Rich and colleagues collected routine clinical data from treating healthcare professionals and patients during standard medical care. Patients and clinicians completed surveys reflecting their experiences with C3G or IC-MPGN. Fatigue was measured using the self-reported FACIT-Fatigue scale of 0–52, where increased scores indicated less fatigue and better quality of life. Investigators assessed proteinuria through 24-hour urine protein levels (g/24h).

In the C3G cohort, 93 clinicians returned data for 289 patients, and 52 patients completed self-reported surveys. In the IC-MPGN cohort, 61 clinicians returned data for 215 patients, and 54 patients completed surveys.

Investigators reported similar baseline clinical characteristics and comorbidity rates for both groups. Of note to Rich and colleagues, a majority of both patient groups, 81% in C3G and 89% in IC-MPGN, had stable or improving disease. Overall, average 24-hour proteinuria levels were 2.3 g/24 hours for C3G and 1.6 g/24 hours for IC-MPGN.

Rich and colleagues observed differences in reported symptoms from the clinician and patient perspectives. The most commonly reported symptom by physicians was proteinuria in both C3G (69%) and IC-MPGN (56%). Whereas, most patients reported fatigue or lower energy (50% and 53%), emphasizing their perceived quality of life impacts.

Patient-reported mean FACIT-Fatigue scores were 34.7 for C3G and 34.9 for IC-MPGN. Annually, patients averaged 12.3 physician visits for C3G and 10.7 for IC-MPGN, underscoring the ongoing healthcare burden observed by investigators. Full-time employment was reported by 58% of patients with C3G and 69% of those with IC-MPGN.¹

Caregiver support was reported for 15% of patients with C3G and 25% of those with IC-MPGN, further emphasizing the broader family and interpersonal burden investigators have associated with these diseases.¹

“Despite slowly progressing disease in the current cohort, C3G and primary IC-MPGN create a significant clinical, economic, and healthcare burden among affected patients and their families,” the investigators concluded.

Caravaca-Fontan F, Norouzi S, Huang M, et al. Real-World Patient Characteristics, Burden, and Quality of Life in C3 Glomerulopathy and Primary Immune Complex Membranoproliferative Glomerulonephritis. 

. Published online December 8, 2025. doi:10.34067/KID.0000001059

C3 Glomerulonephritis & IC-MPGN: The European Rare Kidney Disease Reference Network for Patients. Erknet.org. Published 2015. Accessed December 19, 2025. 

https://www.erknet.org/patients/your-kidney-disease/c3g-ic-mpgn/disease-information

Fontan FC, Aris ÁM, Moreno M, Jorge MV, Nafissi J, Terente MP. #3469 Socioeconomic and psycho-emotional impact of C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis in adult patients in Spain. Nephrology Dialysis Transplantation. Accessed December 15, 2025. doi:

C3 glomerulopathy (C3G) and primary immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) significantly impact patients and caregivers, despite many experiencing stable or improving disease progression. These rare kidney diseases manifest through symptoms like proteinuria, fatigue, and hypertension, often diagnosed incidentally. The study highlights the substantial clinical, economic, and quality-of-life burdens, with frequent healthcare visits and hospitalizations. Surveys revealed differences in symptom reporting between clinicians and patients, emphasizing fatigue's impact on quality of life. The study underscores the need for comprehensive understanding and management of these conditions.

A multinational survey suggests even slowly progressing C3G and IC-MPGN substantially affect patients, caregivers, and healthcare systems.


C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

C3G, IC-MPGN Report A Disruptive Burden Regardless of Slowed Disease Progression 

Barriers to Using PCSK9-Targeting Therapies

The panelists address the real-world barriers that continue to limit the use of PCSK9-targeting therapies in ASCVD care. Despite strong evidence supporting their efficacy and safety, the experts note that cost, insurance restrictions, and prior authorization delays remain the most significant obstacles to access. Many patients who qualify under current guidelines face long approval processes or denials, leading to treatment gaps and frustration for both patients and clinicians. The panel also highlights the burden on healthcare teams, who spend substantial time navigating paperwork and appeals. Even when access is granted, lack of awareness or familiarity among some clinicians can delay therapy initiation. The experts emphasize that broader education, simplified approval pathways, and improved affordability are essential to expanding use. They conclude that overcoming these administrative and systemic hurdles is critical to ensuring more patients benefit from potent LDL-C–lowering therapies proven to reduce recurrent ASCVD events.

Videos

Explore the barriers to PCSK9 inhibitors, their underuse, and how addressing misconceptions can enhance patient outcomes in cholesterol management.

Video Series

Experts discuss evolving strategies in atherosclerosis prevention, emphasizing early intervention and the importance of cholesterol monitoring for better patient outcomes.

Rethinking Prevention in ASCVD Through Cumulative LDL Exposure

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The MASH/MASLD year in review highlights FDA approvals, resmetirom data, semaglutide, pemvidutide, and advances in fibrosis and noninvasive endpoints in 2025.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

MASH/MASLD in 2025: Year in Review

Findings from a retrospective observational cohort study indicate podometrics may inform a less invasive treatment approach in IgA nephropathy (IgAN).


IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Podometrics Could Guide IgAN Treatment While Reducing Invasiveness

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

To stay informed, catch up on some of the most notable alopecia areata news headlines from 2025 with our Year in Review.

Alopecia in 2025: Year in Review

Sayna Norouzi, MD, is an assistant professor of medicine, clinical nephrologist, and founder and director of the glomerular disease and polycystic kidney disease clinics at Loma Linda University Medical Center.

In this segment, the panel discusses how monitoring strategies will need to adapt as B-cell–targeted therapies such as atacicept, sibeprenlimab, and povetacicept move into broader clinical use.

Monitoring Considerations with Emerging B-Cell Modulators in IgAN

In this segment, the panel reviews the emerging clinical data for two additional BAFF/APRIL–pathway inhibitors: sibeprenlimab and povetacicept. 

Additional Emerging BAFF and APRIL Inhibitors in IgAN

A study found that higher PM2.5 exposure during the first year after NICU discharge increased asthma risk in children with bronchopulmonary dysplasia by age 5.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia

Shervin Assassi, MD, is the director of the division of rheumatology at McGovern Medical School, UTHealth Houston.

Assassi reflects on the FDA approval of nerandomilast for progressive pulmonary fibrosis and the clinical benefits of the new PDE4B-targeted treatment option.

Pulmonary Fibrosis

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Nerandomilast Approval Expands Treatment Options for PPF, With Shervin Assassi, MD

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Podcasts

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Diabetes Dialogue: Orforglipron, Cagrilintide, and the Libre Assist

The approval is based on the 64-week phase 3 OASIS 4 trial showing anaverage weight loss of ~17% if all patients stayed on treatment with semaglutide and ~14% regardless of if patients stayed on treatment.

Latest News

Dyslipidemia in 2025: Year in Review

FDA Approves FUROSCIX On-Body Injector for Pediatric Patients, Accepts sNDA for ReadyFlow Autoinjector

Psychological Distress Greater in Patients With Androgenetic Alopecia

C3G, IC-MPGN Report A Disruptive Burden Regardless of Slowed Disease Progression

Barriers to Using PCSK9-Targeting Therapies